AMPH Amphastar Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AMPH

Price (delayed)

$58.3

Market cap

$2.79B

P/E Ratio

20.9

Dividend/share

N/A

EPS

$2.79

Enterprise value

$3.19B

Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active ...

Highlights
The EPS has soared by 77% YoY and by 33% from the previous quarter
The net income has soared by 75% YoY and by 33% from the previous quarter
The stock's P/E is 81% less than its 5-year quarterly average of 109.1 but 6% more than its last 4 quarters average of 19.6
Amphastar Pharmaceuticals's quick ratio has surged by 51% QoQ but it has decreased by 36% YoY
AMPH's debt is up by 27% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.amphastar.com
Peers: MRNS SCYX AGRX TNXP

Key stats

What are the main financial stats of AMPH
Market
Shares outstanding
47.91M
Market cap
$2.79B
Enterprise value
$3.19B
Valuations
Price to earnings (P/E)
20.9
Price to book (P/B)
4.79
Price to sales (P/S)
4.72
EV/EBIT
16.99
EV/EBITDA
14.76
EV/Sales
5.31
Earnings
Revenue
$601.31M
EBIT
$187.97M
EBITDA
$216.41M
Free cash flow
$139.83M
Per share
EPS
$2.79
Free cash flow per share
$2.87
Book value per share
$12.18
Revenue per share
$12.35
TBVPS
$19
Balance sheet
Total assets
$1.54B
Total liabilities
$949.49M
Debt
$672.56M
Equity
$595.14M
Working capital
$285.04M
Liquidity
Debt to equity
1.13
Current ratio
2.1
Quick ratio
1.65
Net debt/EBITDA
1.86
Margins
EBITDA margin
36%
Gross margin
54.2%
Net margin
22.5%
Operating margin
30.1%
Efficiency
Return on assets
12.2%
Return on equity
23.9%
Return on invested capital
24.6%
Return on capital employed
14.6%
Return on sales
31.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AMPH stock price

How has the Amphastar Pharmaceuticals stock price performed over time
Intraday
0.14%
1 week
4.59%
1 month
24.49%
1 year
102.29%
YTD
108.07%
QTD
26.77%

Financial performance

How have Amphastar Pharmaceuticals's revenue and profit performed over time
Revenue
$601.31M
Gross profit
$326.15M
Operating income
$180.84M
Net income
$135.29M
Gross margin
54.2%
Net margin
22.5%
The operating income has surged by 93% year-on-year and by 38% since the previous quarter
The net income has soared by 75% YoY and by 33% from the previous quarter
AMPH's operating margin has soared by 55% year-on-year and by 24% since the previous quarter
AMPH's net margin is up by 42% year-on-year and by 20% since the previous quarter

Growth

What is Amphastar Pharmaceuticals's growth rate over time

Valuation

What is Amphastar Pharmaceuticals stock price valuation
AMPH P/E details
P/E
20.9
P/B
4.79
P/S
4.72
EV/EBIT
16.99
EV/EBITDA
14.76
EV/Sales
5.31
The stock's P/E is 81% less than its 5-year quarterly average of 109.1 but 6% more than its last 4 quarters average of 19.6
The EPS has soared by 77% YoY and by 33% from the previous quarter
The price to book (P/B) is 71% higher than the 5-year quarterly average of 2.8 and 33% higher than the last 4 quarters average of 3.6
Amphastar Pharmaceuticals's equity has increased by 18% YoY
AMPH's price to sales (P/S) is 57% more than its 5-year quarterly average of 3.0 and 24% more than its last 4 quarters average of 3.8
Amphastar Pharmaceuticals's revenue has increased by 24% YoY and by 11% QoQ

Efficiency

How efficient is Amphastar Pharmaceuticals business performance
The ROE has grown by 49% YoY and by 27% from the previous quarter
The ROS has grown by 48% YoY and by 26% from the previous quarter
The ROIC is up by 24% year-on-year and by 16% since the previous quarter
The company's return on assets rose by 12% YoY and by 8% QoQ

Dividends

What is AMPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMPH.

Financial health

How did Amphastar Pharmaceuticals financials performed over time
The total assets is 63% greater than the total liabilities
The total assets has surged by 113% year-on-year and by 12% since the previous quarter
Amphastar Pharmaceuticals's quick ratio has surged by 51% QoQ but it has decreased by 36% YoY
AMPH's debt is 13% greater than its equity
AMPH's debt is up by 27% since the previous quarter
Amphastar Pharmaceuticals's debt to equity has increased by 26% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.